Placebo News and Research

RSS

Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Results from a new clinical trial show that a specialized oral nutrition supplement was associated with a 50 percent lower death rate in older malnourished patients with a heart or lung disease 90 days following hospitalization.

18 Jan 2016

Taking up new mental challenges may help maintain cognitive vitality

One of the greatest challenges associated with the growing numbers of aged adults is how to maintain a healthy aging mind. Taking up a new mental challenge such as digital photography or quilting may help maintain cognitive vitality, say researchers reporting in Restorative Neurology and Neuroscience.

18 Jan 2016

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s.

18 Jan 2016

Topiramate drug curbs marijuana use among young smokers, but with serious side effects

Combining the drug topiramate with psychological counseling curbed marijuana use among young smokers significantly more than did counseling alone, according to newly published results of a small randomized, controlled trial at Brown University. The results come with a caveat, however: many study volunteers couldn't tolerate the medicine's side effects.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARC® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease.

12 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centres across the country -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's.

12 Jan 2016

Early promise for cannabis extract treatment in epilepsy

A preliminary, open-label study suggests that cannabidiol may be a useful adjunctive treatment in adults and children with intractable epilepsy.

7 Jan 2016

Elsevier's new open access journal features novel method to make cancer clinical trials more effective

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials.

7 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

New phase III trial takes intravaginal DHEA a step closer to approval

A new phase III trial with positive results is taking intravaginal DHEA a step closer to governmental approval. The formulation could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after menopause.

5 Jan 2016

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB.

5 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center.

24 Dec 2015

Closing patient knowledge gap could encourage cancer patients to enroll in clinical trials

A five-center national study led by Neal Meropol, MD, and a team of researchers from Case Western Reserve University School of Medicine and University Hospitals Case Medical Center demonstrated that a little information goes a long way in encouraging cancer patients to enroll in clinical trials, a decision that could be potentially lifesaving.

24 Dec 2015

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure.

24 Dec 2015

Placebo News and Research

Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Taking up new mental challenges may help maintain cognitive vitality

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Topiramate drug curbs marijuana use among young smokers, but with serious side effects

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

Early promise for cannabis extract treatment in epilepsy

Elsevier's new open access journal features novel method to make cancer clinical trials more effective

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

New phase III trial takes intravaginal DHEA a step closer to approval

Antiscarring paste can halt fibrosis caused by radiation treatment

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Closing patient knowledge gap could encourage cancer patients to enroll in clinical trials

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News